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pAbstract
Background: This paper is the first in a series of invited perspectives by four
pioneers of Nuclear Medicine imaging and physics. A medical physicist and a
Nuclear Medicine clinical specialist each take a backward look and a forward look at
the contributions of Medical Physics to Nuclear Medicine.
Discussion: Contributions of Medical Physics are presented from the early discovery
of radioactivity, development of first imaging devices, computers and emission
tomography to recent development of hybrid imaging.
Summary: There is evidence of significant contribution of Medical Physics
throughout the development of Nuclear Medicine.
Keywords: Nuclear Medicine; Physics; HistoryBackground
Nuclear Medicine has its basis in ‘the use of radioactive tracers for medical diagnosis,
therapy’. Since the inception of the discipline, the adoption of scientific methods and
instruments has been central to its development and practice. Even today, the Nuclear
Medicine service, at least in the larger tertiary medical centres and teaching hospitals,
involves a team of individuals that includes scientists, clinicians, technologists, nurses
and ancillary staff. The strength of Nuclear Medicine continues to be its unique sensi-
tivity to picomolar concentrations of radiotracer that can be used to probe underlying
physiological, biochemical and molecular processes. The exploitation of this capability
continues to rely on joint ingenuity of scientific and clinical specialists.
The origins of Nuclear Medicine arose from the disciplines of both chemistry and
physics (notably Marie Sklodowska Curie was awarded Nobel prizes in both fields).
Chemistry was central to the discovery and production of radionuclides that are suit-
able for use in humans, and the development of specific radiolabelled compounds con-
tinues to challenge radiochemists and is central to evolving clinical practice. Equally
important has been the development of instrumentation and image analysis tools for
measurement and depiction of the in vivo radiotracer distribution that has involved a
range of scientific disciplines. The focus in this article is on this latter group of scien-
tists, collectively referred to as ‘medical physicists’, but including physicists, engineers,
computer scientists, mathematicians and statisticians (including technologically ori-
ented clinicians) who all contribute to the technological development that underpins
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amples will be used to highlight the continuing significant clinical impact that medical
physicists contribute to the field. Readers are referred to some general texts [1-4] and
historical reviews [5-10] that provide more detailed description of technological devel-
opments in addition to selected key articles.
Discussion
Pre 1940: early pioneers
Clearly, the discovery of radioactivity by Henri Becquerel (1896) [11] and radium by
Pierre and Marie Curie (1898) [12,13] sets the scene for the whole discipline, and as
early as 1913, the tracer principle was enunciated by Georg de Hevesy (a chemist) [14]
leading to early use of radionuclides in humans by Blumgart and Weiss [15] and the
first external radiation detectors. The invention of the cyclotron in 1932 by Ernest
Lawrence (an engineer) [16], and subsequently the nuclear reactor, led very quickly to
the production of useful radionuclides (e.g. iodine-131) [17] which were immediately
used in early clinical studies [18]. Effectively, Nuclear Medicine was born.
1940 to 1960: from measurement to images
Early inventions of scintillation probes and counters as well as the Geiger counter
continue to be used today in a range of applications, although limited in providing
any spatial information (see [19]). They did however facilitate the development of dy-
namic studies to evaluate function and an early interest in understanding tracer dilu-
tion and uptake patterns, techniques that still permeate Nuclear Medicine practice,
especially in the research setting. These formed the basis for clinical studies of renal
function and cerebral blood flow. The invention of the rectilinear scanner by Benedict
Cassen in 1951 [20], however, provided for the first time an image of the radiotracer
distribution. This scanner in combination with in vitro studies and probe-based dy-
namic measurements provided the tools for early establishment of many Nuclear
Medicine centres worldwide (in combination with use of radionuclides for therapy).
But probably the invention that has had the highest impact on Nuclear Medicine
practice is that of the gamma camera by Hal Anger in 1958 [21]. Detection of positron
emission by coincidence detection using probes predated this [22,23], but early imaging
was mainly limited to single photon detection using either a rectilinear scanner or
gamma camera.
1960 to 1980: computing and the birth of emission tomography
It took several years for the gamma camera to appear on the commercial market, and
in the ensuing years, there was significant development of tomographic devices, initially
based on probe systems but subsequently based on use of the basic gamma camera.
David Kuhl is credited with development of the first tomographic systems (both emission
and transmission) with reconstruction involving optical back projection without use of a
computer [24,25]. It should be remembered that computers were in their infancy at that
time and researchers had to resort to innovative alternatives in order to reconstruct even
crude images. It was not until the early 1970s [26] that computer-based reconstruction
was introduced, very much influenced by the introduction of X-ray CT and availability of
filtered back projection. In the meantime, a number of novel approaches were developed
including focal plane (limited angle) tomography and early studies where the patient was
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most current single photon emission computed tomography (SPECT) systems, was first
introduced by John Keyes in 1977 [28], with commercial demonstration by Ron Jaszczak
around the same time [29].
The development of positron emission tomography (PET) followed a similar course
with the earliest dual planar systems developed by Gordon Brownell at Mass General
[30], and the first ring systems built in the early 1970s by Robertson, Yamamoto and
colleagues at Brookhaven [31] and Michael Ter-Pogossian in conjunction with Mike
Phelps and Ed Hoffman [32], who went on to install the first commercial system in
1976 and pioneer further early PET systems at UCLA. As with other sectors of Nuclear
Medicine, it was the combination of chemistry (synthesis of FDG) and engineering/
physics (development of medical cyclotrons and robust PET cameras) that triggered the
widespread use of PET, initially as a research system but ultimately as an important
clinical tool.1980 to 2000: emission tomography comes of age
Both SPECT and PET became more widely available in this period of consolidation
with both modalities being demonstrated to have health impact that justified their clin-
ical use. During this period, early deficiencies were recognised and rectified and robust
commercial systems developed. In the case of SPECT, this involved adoption of dual
detectors and robust rotation gantries rather than the initial counter-balanced single
head systems. PET systems benefitted from new technology (block detectors) initially
using BGO and later LSO and LYSO. An important contributor to the efficacy of tomo-
graphic imaging was the development of iterative reconstruction based on maximum
likelihood (MLEM) [33,34], especially the accelerated form based on ordered subsets
(OSEM) [35], which permitted computationally demanding algorithms to perform in a
clinically acceptable time. The recent resurgence of time-of-flight measurement on sys-
tems using faster scintillators takes advantage of iterative reconstruction to provide
signal-to-noise benefit.
The greater clinical demand for SPECT has also stimulated further novel systems
specifically designed for a specific purpose (e.g. cardiac [36-38]). Previous focus on
neurological systems proved less popular outside the research setting. These sys-
tems have taken advantage of detector technology (e.g. CZT) that has more recently
been translated from high-energy physics laboratories, resulting in compact systems
that have improved performance compared to the traditional gamma camera. These
systems also offer potential for novel acquisition, adapting to the specific patient or
study. As with most of the tomographic systems, developments in technology have
driven the application, providing increasingly superior image quality and diagnostic
capability.2000 to present: hybrid imaging takes over
Both PET and SPECT benefit from attenuation correction based on direct estimation of
the in vivo attenuation by means of transmission measurement [39,40]. Developments
of transmission systems for PET and SPECT were both based on external sources that
could provide attenuation maps for correction. However, these were typically of poor
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study. Bruce Hasegawa initially suggested use of CT [41], leading to the introduction of a
‘low-cost, low-dose’ SPECT/CT in 1999 by GE Healthcare [42]. Subsequent developments
have led to a range of fully diagnostic SPECT/CT systems. In the case of PET/CT,
this was conceived initially in Geneva by David Townsend and colleagues, then de-
veloped at Pittsburgh (in conjunction with Ron Nutt at CTI) [43-45] and ultimately
introduced commercially in 2000. The impact of PET/CT has been particularly im-
pressive as the added diagnostic value of the combined modalities has by far
exceeded expectations rather than simply providing efficient high-quality transmis-
sion measurement for the purpose of attenuation correction [46,47].
The most recent hybrid imaging combination to be commercially released is PET/
MRI, opening further potential for combining information and exploring joint syner-
gies. This is another fine example of how innovative technology deriving outside the
medical field (in this case, solid state readout systems that replace the photomultiplier
of the conventional detector) can be adapted for benefit (magnetic compatibility,
compact design, improved performance). The early developments in preclinical systems,
e.g. [48], rapidly led to the introduction of paired sequential PET/MRI systems before the
first demonstration of simultaneous PET/MRI in human neurological studies, quickly
followed by whole-body applications [49,50]. SPECT/MRI is not commercially available at
this time, but development is in progress [51]; whether this proves clinically useful re-
mains to be seen.Figure 1 Some of the many scientists who have contributed to Nuclear Medicine. Top row (left to
right): Henri Becquerel, Marie Sklodowska Curie, Georg de Hevesy, Ernest Lawrence and Benadict Cassen.
Middle row: Hal Anger, David Kuhl, Gerd Muehllehner, Ron Jaszczak and Bruce Hasegawa. Bottom row:
Gordon Brownell, Michael Phelps, Michael Ter-Pogossian, David Townsend and Ron Nutt.
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The brief history above demonstrates very clearly how the growth of Nuclear Medicine
can be attributed, at least in part, to the technological development. This history over-
looks the associated research across the breadth of Nuclear Medicine that has led to
the current practice. This includes international guidelines on radiation safety and
dosimetry, accepted procedures for instrument specification, acceptance testing and
quality control, and standards for digital image storage and transfer. The techniques
used to guarantee image fidelity that are incorporated in commercial systems have
been developed and validated (e.g. uniformity and linearity correction), the software
for various image corrections necessary for quantification has evolved and continues
to be developed (corrections for attenuation, scatter, resolution and motion), and
image analysis software that facilitates quantification, image fusion, kinetic analysis
and disease classification represents enormous international effort with significant im-
pact on current clinical capabilities. The ‘medical physicist’ plays an important role as
a member of the Nuclear Medicine team, providing scientific support in the clinical
setting; equally, he/she continues to innovate and validate techniques that aid in im-
proving the quality of information that can be extracted from medical images as well
as the effectiveness of treatment. There are many active university-based research la-
boratories that continue to focus on the development of medical imaging instrumenta-
tion, image reconstruction and image analysis with many internationally recognised
researchers contributing to the continuing development. It is impossible in this brief
article to give adequate credit to the many individuals who have made major contribu-
tions to the field and have greatly influenced the tools that are available to current
Nuclear Medicine practice (Figure 1). The many Medical Physics mentors and teachers
should also not be overlooked as they have enabled the whole Nuclear Medicine com-
munity. The Medical Physics community also provides the manpower that populates
the laboratories and support staff of the continually developing vendors.Summary
It is hard to overstate the value of the contribution of medical physicists to Nuclear
Medicine. The development of the discipline has been driven by innovation from both
scientists and clinicians. This partnership has been important in defining clinically rele-
vant questions and seeking novel but practical solutions. Technology continues to develop
(e.g. new detector materials and faster computers), and Medical Physics innovation con-
tinues to push the frontiers of what is possible. Effective translation from research labora-
tories to clinics requires specialised expertise and often lacks specific funding. Likewise,
demonstration of clinical utility and impact is an important endeavour that requires dedi-
cated staff or allocation of time, protected from normal clinical support demands. Medical
physicists have been central to the development of Nuclear Medicine and must continue
this essential work.
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